Whisnant J K, Pelkey J
Ann Rheum Dis. 1982;41 Suppl 1(Suppl 1):44-7. doi: 10.1136/ard.41.suppl_1.44.
A retrospective review of the literature has been carried out to determine laboratory abnormalities occurring in patients with rheumatoid arthritis (RA) treated with azathioprine, in order to establish a profile for this agent in the treatment of this disease. A total of 542 patients in 24 studies, reported in the literature, were given a range of doses of azathioprine for up to four years. Fifteen percent of patients were withdrawn because of toxicity. The two major toxic effects were gastrointestinal symptoms and alteration in blood counts. Clinically significant leucopenia (less than 2500/mm3) occurred in 14 of the total of 93 patients reported to have developed leucopenia. Some adverse reactions, which would have been expected from the use of azathioprine in other diseases, were uncommon, namely significant infections, hepatotoxicity and pancreatitis. Adverse experience with azathioprine in rheumatoid arthritis compares well with other slow-acting, or disease modifying, drugs.
为了确定接受硫唑嘌呤治疗的类风湿关节炎（RA）患者出现的实验室异常情况，以便明确该药物在治疗这种疾病中的特征，我们对文献进行了回顾性研究。文献报道的24项研究中，共有542例患者接受了不同剂量的硫唑嘌呤治疗，最长达四年。15%的患者因毒性反应而停药。两种主要的毒性反应是胃肠道症状和血细胞计数改变。在报告出现白细胞减少的93例患者中，有14例出现了具有临床意义的白细胞减少（低于2500/mm³）。一些在其他疾病中使用硫唑嘌呤时可能预期出现的不良反应并不常见，即严重感染、肝毒性和胰腺炎。硫唑嘌呤在类风湿关节炎中的不良反应与其他慢作用或病情改善药物相比情况良好。
